TY - JOUR
T1 - Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome
AU - Ruggenenti, Piero
AU - Ruggiero, Barbara
AU - Cravedi, Paolo
AU - Vivarelli, Marina
AU - Massella, Laura
AU - Marasà, Maddalena
AU - Chianca, Antonietta
AU - Rubis, Nadia
AU - Ene-Iordache, Bogdan
AU - Rudnicki, Michael
AU - Pollastro, Rosa Maria
AU - Capasso, Giovambattista
AU - Pisani, Antonio
AU - Pennesi, Marco
AU - Emma, Francesco
AU - Remuzzi, Giuseppe
PY - 2014/4/1
Y1 - 2014/4/1
N2 - The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic,multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroidinduced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously).At 1 year, allpatientswere in remission: 18were treatment-free and 15 never relapsed.Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2-4) to 0.5 (IQR, 0-1; P2 (P=0.01),with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P
AB - The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic,multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroidinduced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously).At 1 year, allpatientswere in remission: 18were treatment-free and 15 never relapsed.Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2-4) to 0.5 (IQR, 0-1; P2 (P=0.01),with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P
UR - http://www.scopus.com/inward/record.url?scp=84901481342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901481342&partnerID=8YFLogxK
U2 - 10.1681/ASN.2013030251
DO - 10.1681/ASN.2013030251
M3 - Article
C2 - 24480824
AN - SCOPUS:84901481342
VL - 25
SP - 850
EP - 863
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - 4
ER -